|
1
|
Sun M and Kisseleva T: Reversibility of
liver fibrosis. Clin Res Hepatol Gastroenterol. 39 (Suppl
1):S60–S63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carloni V, Luong TV and Rombouts K:
Hepatic stellate cells and extracellular matrix in hepatocellular
carcinoma: More complicated than ever. Liver Int. 34:834–843. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang CY, Yuan WG, He P, Lei JH and Wang
CX: Liver fibrosis and hepatic stellate cells: Etiology,
pathological hallmarks and therapeutic targets. World J
Gastroenterol. 22:10512–10522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Campana L and Iredale JP: Regression of
liver fibrosis. Semin Liver Dis. 37:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zoubek ME, Trautwein C and Strnad P:
Reversal of liver fibrosis: From fiction to reality. Best Pract Res
Clin Gastroenterol. 31:129–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Puche JE, Saiman Y and Friedman SL:
Hepatic stellate cells and liver fibrosis. Compr Physiol.
3:1473–1492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elpek GÖ: Cellular and molecular
mechanisms in the pathogenesis of liver fibrosis: An update. World
J Gastroenterol. 20:7260–7276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh TR, Gupta A and Suravajhala P:
Challenges in the miRNA research. Int J Bioinform Res Appl.
9:576–583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu Q, Yang Z, Shi Y and Fan D: MiRNAs in
human cancers: The diagnostic and therapeutic implications. Curr
Pharm Des. 20:5336–5347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou B, Li Z, Yang H and He N:
Extracellular miRNAs: Origin, function and biomarkers in hepatic
diseases. J Biomed Nanotechnol. 10:2865–2890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He Y, Huang C, Sun X, Long XR, Lv XW and
Li J: MicroRNA-146a modulates TGF-beta1-induced hepatic stellate
cell proliferation by targeting SMAD4. Cell Signal. 24:1923–1930.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng J, Lin Z, Dong P, Lu Z, Gao S, Chen
X, Wu C and Yu F: Activation of hepatic stellate cells is
suppressed by microRNA-150. Int J Mol Med. 32:17–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Venugopal SK, Jiang J, Kim TH, Li Y, Wang
SS, Torok NJ, Wu J and Zern MA: Liver fibrosis causes
downregulation of miRNA-150 and miRNA-194 in hepatic stellate
cells, and their overexpression causes decreased stellate cell
activation. Am J Physiol Gastrointest Liver Physiol. 298:G101–G106.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kitano M and Bloomston PM: Hepatic
stellate cells and microRNAs in pathogenesis of liver fibrosis. J
Clin Med. 5:E382016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He Y, Huang C, Zhang SP, Sun X, Long XR
and Li J: The potential of microRNAs in liver fibrosis. Cell
Signal. 24:2268–2272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ambati RR, Phang SM, Ravi S and
Aswathanarayana RG: Astaxanthin: Sources, extraction, stability,
biological activities and its commercial applications-a review. Mar
Drugs. 12:128–152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen JT and Kotani K: Astaxanthin as a
potential protector of liver function: A review. J Clin Med Res.
8:701–704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Higuera-Ciapara I, Félix-Valenzuela L and
Goycoolea FM: Astaxanthin: A review of its chemistry and
applications. Crit Rev Food Sci Nutr. 46:185–196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fakhri S, Abbaszadeh F, Dargahi L and
Jorjani M: Astaxanthin: A mechanistic review on its biological
activities and health benefits. Pharmacol Res. 136:1–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guerin M, Huntley ME and Olaizola M:
Haematococcus astaxanthin: Applications for human health and
nutrition. Trends Biotechnol. 21:210–216. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roderburg C, Urban GW, Bettermann K, Vucur
M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi
M, et al: Micro-RNA profiling reveals a role for miR-29 in human
and murine liver fibrosis. Hepatology. 53:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Edlich F: BCL-2 proteins and apoptosis:
Recent insights and unknowns. Biochem Biophy Res Commun. 500:26–34.
2018. View Article : Google Scholar
|
|
24
|
Kisseleva T and Brenner DA: Role of
hepatic stellate cells in fibrogenesis and the reversal of
fibrosis. J Gastroenterol Hepatol. 22 (Suppl 1):S73–S78. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Y, Kim B, Park YK, Koo SI and Lee JY:
Astaxanthin prevents TGFβ1-induced pro-fibrogenic gene expression
by inhibiting Smad3 activation in hepatic stellate cells. Biochim
Biophys Acta. 1850:178–185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zou TB, Jia Q, Li HW, Wang CX and Wu HF:
Response surface methodology for ultrasound-assisted extraction of
astaxanthin from Haematococcus pluvialis. Mar Drugs. 11:1644–1655.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang XS, Zhang X, Zhou ML, Zhou XM, Li N,
Li W, Cong ZX, Sun Q, Zhuang Z, Wang CX and Shi JX: Amelioration of
oxidative stress and protection against early brain injury by
astaxanthin after experimental subarachnoid hemorrhage. J
Neurosurg. 121:42–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo SX, Zhou HL, Huang CL, You CG, Fang Q,
Wu P, Wang XG and Han CM: Astaxanthin attenuates early acute kidney
injury following severe burns in rats by ameliorating oxidative
stress and mitochondrial-related apoptosis. Mar Drugs.
13:2105–2123. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ravi Kumar S, Narayan B, Sawada Y,
Hosokawa M and Miyashita K: Combined effect of astaxanthin and
squalene on oxidative stress in vivo. Mol Cell Biochem. 417:57–65.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shen M, Chen K, Lu J, Cheng P, Xu L, Dai
W, Wang F, He L, Zhang Y, Chengfen W, et al: Protective effect of
astaxanthin on liver fibrosis through modulation of TGF-β1
expression and autophagy. Mediators Inflamm. 2014:9545022014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Böttcher K and Pinzani M: Pathophysiology
of liver fibrosis and the methodological barriers to the
development of anti-fibrogenic agents. Adv Drug Deliv Rev. 121:3–8.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schuppan D and Kim YO: Evolving therapies
for liver fibrosis. J Clin Invest. 123:1887–1901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bansal R, Nagorniewicz B and Prakash J:
Clinical advancements in the targeted therapies against liver
fibrosis. Mediators Inflamm. 2016:76297242016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tutar L, Tutar E and Tutar Y: MicroRNAs
and cancer; an overview. Curr Pharm Biotechnol. 15:430–437. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shin VY and Chu KM: MiRNA as potential
biomarkers and therapeutic targets for gastric cancer. World J
Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feng B, Zhang K, Wang R and Chen L:
Non-small-cell lung cancer and miRNAs: Novel biomarkers and
promising tools for treatment. Clin Sci (Lond). 128:619–634. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song SJ and Pandolfi PP: MicroRNAs in the
pathogenesis of myelodysplastic syndromes and myeloid leukaemia.
Curr Opin Hematol. 21:276–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kaboli PJ, Rahmat A, Ismail P and Ling KH:
MicroRNA-based therapy and breast cancer: A comprehensive review of
novel therapeutic strategies from diagnosis to treatment. Pharmacol
Res. 97:104–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fiserova B, Kubiczkova L, Sedlarikova L,
Hajek R and Sevcikova S: The miR-29 family in hematological
malignancies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
159:184–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liang C, Bu S and Fan X: Suppressive
effect of microRNA-29b on hepatic stellate cell activation and its
crosstalk with TGF-β1/Smad3. Cell Biochem Funct. 34:326–333. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang J, Chu ES, Chen HY, Man K, Go MY,
Huang XR, Lan HY, Sung JJ and Yu J: microRNA-29b prevents liver
fibrosis by attenuating hepatic stellate cell activation and
inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget.
6:7325–7338. 2015.PubMed/NCBI
|
|
42
|
Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB
and Yang JR: The role of miR-29b in cancer: Regulation, function,
and signaling. Onco Targets Ther. 8:539–548. 2015.PubMed/NCBI
|
|
43
|
Li J, Dai W, Xia Y, Chen K, Li S, Liu T,
Zhang R, Wang J, Lu W, Zhou Y, et al: Astaxanthin inhibits
proliferation and induces apoptosis of human hepatocellular
carcinoma cells via inhibition of Nf-κb P65 and Wnt/β-catenin in
vitro. Mar Drugs. 13:6064–6081. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y,
Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis,
tumorigenicity, and prognosis of hepatocellular carcinoma.
Hepatology. 51:836–845. 2010.PubMed/NCBI
|
|
45
|
Mott JL, Kobayashi S, Bronk SF and Gores
GJ: mir-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
|
